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Background—Platelet-activating factor (PAF) is one of the most potent biological mediators of tissue injury. PAF
acetylhydrolase (PAF-AH) is a recently isolated naturally occurring enzyme that hydrolyzes PAF and renders it inactive.
We hypothesize that inhibition of PAF with PAF-AH will reduce myocardial ischemia-reperfusion (I/R) injury in vivo.
Methods and Results—The coronary ligation model was used in New Zealand white rabbits. The large branch of the
marginal coronary artery was occluded for 45 minutes, followed by 2 hours of reperfusion. Fifteen minutes before
reperfusion, animals were given either 2 mg/kg of vehicle or of PAF-AH. At the completion of 120 minutes of
reperfusion, percentage of necrosis, degree of neutrophil infiltration, and measurements of regional contractility were
assessed. Data are expressed as the mean6SEM and compared by Student’stest or Mann-Whitney ANOVA. Both
groups of animals showed an equivalent area at risk; however, 46.7611% was necrotic in the animal treated with
vehicle. In contrast, 20.967.0% was necrotic in the animals treated with PAF-AH (P,0.05). Systolic shortening and
wall thickness were significantly greater in those animals treated with PAF-AH at 15, 30, 60, and 120 minutes of
reperfusion (P,0.05). Quantification of neutrophil infiltration showed a 62% reduction in the PAF-AH treated animals
compared with those treated with vehicle alone.
Conclusions—PAF-AH is a potent cardioprotective agent in an in vivo model of I/R injury.(Circulation. 1999;100[suppl
II]:II-365–II-368.)
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This year, as many as 1.5 million Americans will have anew or recurrent myocardial infarction, and as a direct
result, one third of these people will die.1 Although several
types of interventions exist to treat this disorder, including
PTCA and CABG, significant potential still exists for mor-
bidity and mortality in the form of myocardial ischemia-
reperfusion (I/R) injury.
When the heart is rendered ischemic, a reduction occurs in the
natural antioxidant defenses of the cells. At reperfusion, an
accumulation of reactive oxygen intermediates results in a
change in the redox potential of the cell, known as oxidative
stress. Oxidative stress initiates a host inflammatory response
characterized by widespread neutrophil adhesion and activation,
initiation of coagulation, and alteration in vascular permeability.
Platelet-activating factor (PAF) is a potent biological mediator
of inflammation and has been shown to participate significantly
in I/R injury.2 Under normal physiological conditions, PAF is
minimally expressed; however, under conditions of oxidative
stress, as occurs in I/R injury, PAF is released by neutrophils and
monocytes and is expressed on the outer leaflet of endothelial
cells.3 Once expressed, PAF results in several diverse biological
activities, including neutrophil activation and chemotaxis, alter-
ations in vascular permeability, platelet activation, and negative
inotropy, all of which may contribute to the clinical manifesta-
tions of I/R injury.4,5
The tissues, blood cells, and plasma of the body all have
enzymes that catalyze the hydrolysis of PAF. This self-
protective mechanism limits the damaging effect of PAF.6
Studies with newly available human recombinant PAF-
acetylhydrolase (AH) have shown that it reduces edema,
prevents asthma-related symptoms, and protects animals from
septicemia.7,8 The protective effects of PAF-AH have never
been studied under conditions of myocardial oxidative stress.
The purpose of the present study was to test the hypothesis
that PAF-AH reduces myocardial I/R injury.
Methods
In this model, adult New Zealand White rabbits weighing 3 to 4 kg each
were used in research protocols approved by the Animal Care Commit-
tee of the University of Washington, Seattle. All animals received
humane care according to the “Guide for the Care and Use of
Laboratory Animals” prepared by the National Academy of Sciences
and published by the National Institutes of Health (NIH
publication 85-23).
Reagents
PAF-AH and the vehicle in which it was dissolved were acquired
from ICOS Corp (Bothell, Wash). Both compounds, at a dose of 2
mg/kg, were given intravenously through the marginal ear vein 15
minutes before reperfusion. Twelve animals received PAF-AH: 6
were used for infarct data and 6 for histology. Twelve animals
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received vehicle: 6 were used for infarct data and 6 for histology. To
ensure that recombinant PAF-AH alone had no effect on study end
points, 3 animals received PAF-AH without ischemia; all were used
for regional contractility data and histology.
Surgical Procedure
Rabbits were anesthetized with an initial intramuscular injection of
ketamine (35 mg/kg) and xylazine (5 mg/kg). The rabbits were endo-
tracheally intubated and maintained on inhaled halothane (1% to 2%)
anesthesia in 100% O2 using a small-animal respirator. A 20-gauge
flexible catheter was placed in the left carotid artery to measure heart
rate (HR) and mean arterial pressure and to collect blood samples. The
heart was exposed via median sternotomy. A 5F Millar catheter was
placed through a small pursed-string incision in the left ventricle to
allow estimation of the left ventricular peak systolic pressure, left
ventricular end diastolic pressure, and maximum and minimum change
in left ventricular pressure (dP/dt). One pair of sonometric piezoelectric
crystals was placed on the surface of the heart to assess regional wall
motion abnormalities via segmental shortening (SS) in the area at risk.
Another crystal was tunneled tangentially to the subendocardium, with
a second crystal sutured to the epicardium for measurements of LV wall
thickness (WT) (Sonometrics, Inc). The hemodynamic trace acquired
from the Millar catheter allowed SS and WT measurements to be
correlated with end-diastolic and end-systolic time points. A 4.0 Vicryl
suture was passed twice around a large anterolateral branch of the left
main coronary artery that supplied to most of the left ventricle, and the
ends of the suture passed through a small length of polyethylene tubing
to form a snare. After a 20- to 30-minute stabilization period, baseline
values were recorded. Regional myocardial ischemia was produced by
reversibly occluding the artery for 45 minutes, followed by 120 minutes
of reperfusion. Fifteen minutes before reperfusion, the rabbits received
2.0 mg/kg of PAF-AH or vehicle intravenously. Heart rate, mean arterial
pressure, left ventricular end-systolic pressure, left ventricular end-dia-
stolic pressure,6dP/dt, WT, and SS were recorded at baseline; 30
minutes of ischemia; 45 minutes ischemia; and 15, 30, 60, and 120
minutes after reperfusion. Animals that received PAF-AH alone had the
same measurements recorded at baseline and 15, 30, 60, and 120
minutes after drug administration. After 120 minutes of reperfusion, all
animals were euthanatized with an intravenous bolus of concentrated
pentobarbital, and the myocardial tissue was taken and processed for
calculation of infarct size or histologic analysis.
Determination of Infarct Size
At the completion of the 120-minute reperfusion period, the coronary
artery was reoccluded and 6 mL of 20% Evans blue dye (Sigma
Chemical Co) was injected into the left atrium and allowed to
circulate and stain all perfused tissue. The area supplied by the
ligated vessel remained unstained, which demarcated the myocardi-
um at risk of infarction. After the heart was arrested with pentobar-
bital, it was rapidly excised. The left ventricle was isolated from the
rest of the heart, weighted, and then cut into 2-mm-thick transverse
slices. The normal myocardium (stained blue) was separated from
the area at risk (unstained). The area at risk was placed in a 37°C
solution of 1% triphenyltetrazolium chloride (TTC) for 30 minutes.
TTC stains the viable tissue brick red, which leaves the necrotic zone
pale. The TTC red (noninfarcted) tissue is separated from the TTC
pale (necrotic) tissue, and each area is weighed. The left ventricular
area at risk was calculated as the sum of the noninfarcted and
necrotic tissue weight of the tissue perfused by the occluded vessel
divided by the weight of the left ventricle, expressed as a percentage.
The left ventricular area of necrosis was calculated as the weight of
necrotic tissue divided by the weight of the left ventricle, expressed
as a percentage. The infarct size was calculated by dividing the
weight of the TTC pale tissue by the weight of the total area at risk
(left ventricular area of necrosis/left ventricular area at risk).
Determination of Regional Contractility
End-diastolic length, end-systolic length, and WT were determined
from the strip-chart recording by an observer blinded to the study
design. Percentage SS of baseline was calculated by the following
equation: 1003[(EDL2ESL)/EDSB]5%SS, where EDL indicates
end-diastolic length; ESL, end-systolic length; and EDSB, end-dia-
stolic length–end systolic length at baseline. Percentage WT change
was calculated by the following equation: 1003(ESW2EDW/
EDSB)5%Change in WT, where ESW indicates end-systolic width;
EDW, end-diastolic width; and EDSB, end-systolic width minus
end-diastolic width at baseline.
Determination of Neutrophil Infiltration
Neutrophil accumulation in the heart was quantified in the following
manner: A tissue block measuring'1.031.030.5 cm was randomly
selected from each rabbit heart. The blocks were dehydrated and
embedded in paraffin, and 3-mm sections were placed on glass
slides. The slides were stained with hematoxylin and eosin. A
pathologist blinded to the study protocol counted the number of
neutrophils in 10 randomly selected fields (2200mm2).
Statistical Analysis
The data analysis was performed using SPSS for Windows, version
6.1. For each of the treatment groups, several parameters (expressed
as continuous variables) were studied at the indicated time points. To
determine whether a statistically significant change had occurred
compared with the baseline value, the parameters were compared
with baseline by use of pairedt tests. For intergroup comparisons, the
mean change (from baseline) for each of these parameters was
analyzed at the specific time points using ANOVA. The Mann-
Whitney test was used for post hoc comparisons. A probability value
of ,0.05 was considered statistically significant.
Results
PAF-AH Reduces Infarct Size
The percentages of areas at risk for infarction were similar in both
groups (vehicle, 44.36 4.3%; PAF-AH, 46.736 2.7%) as depicted
in Figure 1. However, infarct size was markedly reduced in the
group treated with PAF-AH (20.9763.3%) compared with the
vehicle-treated group (45.7266.5%),P,0.05.
PAF-AH Reduces Regional Myocardial Wall
Motion Abnormalities
Wall Thickness
A similar reduction in WT after coronary occlusion occurred
in both vehicle and PAF-AH groups (34% vehicle versus
49% PAF-AH group). By 120 minutes after reperfusion, the
vehicle-treated animals had recovered to an average of only
45% of the baseline value, whereas the PAF-AH–treated
group had recovered to an average of 85% of the baseline
value (Figure 2). Animals that received PAF-AH alone
maintained nearly 100% of the baseline value throughout the
entire sampling period (data not shown).
Systolic Shortening
Coronary occlusion similarly reduced systolic shortening to 50%
and 75% of baseline values in the vehicle and PAF-AH treated
groups, respectively. However, after 120 minutes of reperfusion,
the vehicle group had recovered only 54.5% of its baseline
regional contractile function, whereas the PAF-AH group recov-
ered to 103% of its baseline value (Figure 2). Animals that
received PAF-AH alone maintained 100% of the baseline value
throughout the sampling period (data not shown).
PAF-AH Reduces Neutrophil Infiltration
Histologic examination of myocardial tissue after I/R in the
area at risk for infarction, revealed marked endothelial-
leukocyte adhesion and transendothelial migration in those
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animals receiving vehicle alone. In PAF-AH-treated animals,
in contrast, neutrophil adherence was markedly reduced.
Animals treated with vehicle alone had 157 polymorphonu-
clear neutrophils (PMNs) per high-powered field compared
with 75 PMNs per high-powered field in PAF-AH–treated
animals. Animals that received PAF-AH in the absence of
ischemia averaged only 1 PMN per high-powered field (data
not shown). These results suggest that PAF-AH inhibited
neutrophil–endothelial cell interactions in vivo, although the
difference in neutrophil accumulation was not significant
(Figures 3 and 4). The enzyme alone appears to have no effect
on neutrophil activation and migration, which correlates with
unpublished data in the lung, kidney, and pancreas (Brian
Schimpf, PhD, personal communication with ICOS, 1999).
Discussion
These results suggest that PAF plays a role in the regional
cardiac dysfunction associated with I/R injury. The adminis-
tration of its natural inhibitor, PAF-AH, markedly reduces
this injury. Specifically, PAF-AH reduces infarct size and
enhances regional ventricular functional recovery after I/R.
Several mechanisms exist by which PAF-AH may reduce I/R
injury. One of the cardioprotective features of PAF-AH may
stem from its ability to modulate leukocyte-endothelium inter-
Figure 1. Reduction in necrosis in PAF-
AH–treated animals. Values are
mean6SEM; n56. Significance of differ-
ence, *P,0.05.
Figure 2. Alterations in regional contractile function. Tie indi-
cates coronary ligation and initiation of ischemia. Values are
mean6SEM; n56. Significance of difference, *P,0.05.
Figure 3. Histologic hematoxylin-and-eosin slides viewed at
3100 that show notable neutrophil adherence and infiltration in
the vehicle-treated animals, which is diminished in animals that
received PAF-AH.
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actions. The endothelial cell, when exposed to conditions of
oxidative stress, synthesizes PAF within minutes and transports
it to the plasma membrane, at which it is expressed on the outer
leaflet of the plasma membrane. Once expressed, PAF serves as
both a chemoattractant and activator of neutrophils, which
results in neutrophil-endothelial adherence, superoxide anion
release, and degranulation.2,3 Furthermore, PAF may also result
in vasoconstriction,9 alteration in vascular permeability,10 and
negative ionotropy11 in the setting of I/R. Any of these biological
activities could explain the beneficial effect that exogenous
administration of PAF-AH has in our model.
Much of the evidence implicating the role of PAF in I/R
injury has been acquired through the use of PAF antagonists.
PAF antagonists used in in vivo models of I/R have proved to
be cardioprotective, as indicated in functional measurements
such as pressure-volume loops in swine,11 dP/dt in sheep,12
and systolic developed pressure in rabbits.13 Their use has
also resulted in reduction of infarct size in the reperfused
myocardium and inhibition of reperfusion-induced coronary
artery vasoconstriction.14 Although these antagonists have
proven to be a valuable research tool for elucidation of the
role of PAF in I/R injury, they have also proven to be
problematic when used clinically. Their detrimental effects
include PAF agonist activities at high concentrations, antag-
onism of ADP and collagen production, significant hemoly-
sis, and vascular damage.2
In 1995, the cDNA encoding the plasma form of PAF-AH
was cloned.8 The primary structure of plasma PAF-AH is
unique. Its active site contains a catalytic triad found in many
phospholipases that contains a serine, an acidic (usually
aspartate), and a histidine residue. This catalytic triad hydro-
lyzes the acyl group at the second position of glycerol
moieties. However, PAF-AH, unlike other phospholipases,
has marked selectivity for phospholipids with short acyl
chains at the sn-2 positions.7 Thus, normal membrane phos-
pholipids are protected from hydrolysis by an intrinsic prop-
erty of the enzyme. This same selective activity highlights its
ability to be the most specific inhibitor of PAF known. As a
result, this recombinant enzyme lacks the detrimental, non-
selective activity of other PAF antagonists.
Early experience with PAF-AH in clinical trials has shown it to
be a safe and efficacious means to treat inflammatory-mediated
pulmonary dysfunction. Additionally, an increase in PAF levels has
been documented during cardiac surgery with cardiopulmonary
bypass. This finding did not correlate with a difference in serum
PAF-AH activity.15 Therefore, exogenous administration of
PAF-AH may prove to be a viable clinical means to reduce the
detrimental activity of excessive PAF, which could result in a
reduction in both myocardial injury and the generalized inflamma-
tory consequences of cardiopulmonary bypass.
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